Wall Street Loves this New Immunotherapy Cancer Drug


As new immunotherapy drugs hope to turn metastatic cancer into a chronic manageable condition, or at least significantly prolong life in the near term, investors are understandably excited about their potential.

And one company at the forefront of this move, Bristol-Myers Squibb, just got a huge upgrade today from Wall Street titan Citigroup, sending shares 5% higher. Citi moved Bristol from "neutral" to "buy" and upped its old $33 price target to $55 per share.

In this video, health-care analyst David Williamson discusses Bristol's big upgrade and gives a few of his key takeaways from the report.

Another topic health care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.

Follow David on Twitter: @MotleyDavid.

The article Wall Street Loves this New Immunotherapy Cancer Drug originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool owns shares of Citigroup. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published